Notably, while the allele frequency of PNPLA3-Lys434Glu was significantly associated with MASLD risk (Table 1), its genotype frequencies did not reach statistical significance (Table 2), suggesting a potential dose-dependent effect that requires further validation. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.